Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/VRTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $482.00, up 0.31% today, with a bullish technical signal and strong fundamentals including a 35.51% net income margin and recent earnings beats. The company's $10 billion acquisition of Crinetics Pharmaceuticals, announced on July 8, 2026, aims to expand its endocrinology portfolio, potentially adding $5 billion in peak annual sales. Revenue grew to $12.0 billion in 2025, recovering from a net loss in 2024, with operating cash flow strengthening to $3.63 billion.
The outlook remains positive with an 85.7% analyst buy rating and a $538 consensus price target, though integration risks from the acquisition and competitive pressures in biotech pose challenges. Earnings growth and pipeline expansion are key catalysts for further upside, supported by robust cash generation and high profitability metrics.
Read full analysis

Key Stats

  • Market Cap
    $119.94B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $529.59
  • 52W Low
    $366.54
  • Typical Hold Time
    -
  • Enterprise Value
    $114.68B
  • Div Yield
    -
  • Trading Activity
    -
$474
52W Low: $366.54
08 Aug 2025
52W High: $529.59
06 Jul 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $529.59, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Investec Bank discloses share dealings in Advanced Medical Solutions Group Plc on July 23, 2026

Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on July 23, 2026. The bank purchased 640,099 ordinary shares at prices between 280 and 280.25 per unit and sold 650,000 sh...

Market News
2 hours ago
Na
Neutral
pluang ai news

Global cleanroom lighting market to reach $1.54B by 2035, driven by semiconductor and pharma growth.

The global cleanroom lighting market is projected to grow from $0.90 billion in 2025 to $1.54 billion by 2035, at a CAGR of 5.5%. Growth is fueled by expanding semiconductor manufacturing, pharmaceutical production, and regulatory demands for contami...

Market News
3 hours ago
Sns Insider
Bullish
news icon
pluang ai news

Resolution Minerals gains second US FAST-41 status for Golden Gate, speeding permitting for tungsten-gold project.

Resolution Minerals secured its second US Federal FAST-41 Transparency coverage for the Golden Gate tungsten-gold target in Idaho, following a prior designation for Antimony Ridge. This federal status prioritizes the project within the permitting pro...

Market News
4 hours ago
Proactive Investors - Finance
Bullish
news icon
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $119.94B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $529.59
  • 52W Low
    $366.54
  • Typical Hold Time
    -
  • Enterprise Value
    $114.68B
  • Div Yield
    -
  • Trading Activity
    -
$474
52W Low: $366.54
08 Aug 2025
52W High: $529.59
06 Jul 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $529.59, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!